Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Invion ( (AU:IVX) ) has provided an update.
Invion reported a cash balance of A$138,000 at 31 December 2025, but has since bolstered its funding with a A$1.3 million convertible note raising and a A$400,000 R&D advance facility, while also fully repaying its obligations to Lind Global Fund II LP. Operationally, the quarter marked a series of strategic milestones: a non-dilutive grant-backed collaboration with South Korea’s Hanlim Pharm to provide up to US$2 million for preclinical and regulatory work ahead of a first-in-human Australian trial of intravenous INV043 for oesophageal cancer; an expanded perpetual, exclusive global licence over the Photosoft™ technology across multiple human and animal disease indications, significantly strengthening Invion’s long-term platform and partnering prospects; and a funded collaboration with Taiwan-listed Protect Animal Health to run Photosoft-based cancer studies in companion animals, with Invion retaining all technology and IP rights. Collectively, these developments support Invion’s shift from pure R&D towards a more commercially oriented platform position in both human and veterinary oncology, while addressing urgent unmet needs in oesophageal and companion animal cancers and reinforcing confidence from international partners and key shareholders.
The most recent analyst rating on (AU:IVX) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Invion stock, see the AU:IVX Stock Forecast page.
More about Invion
Invion Limited is an Australian biotechnology company focused on developing its proprietary Photosoft™ photodynamic therapy platform for oncology and other disease indications in both human and animal health. The company targets large unmet medical needs, including difficult-to-treat cancers, and seeks to commercialise Photosoft globally through clinical programs, licensing, and strategic partnerships across human and companion animal markets.
Average Trading Volume: 110,101
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$7.88M
See more data about IVX stock on TipRanks’ Stock Analysis page.